abstract |
Use of a combination of a TLR agonist and an immune checkpoint inhibitor in preparation of drugs for treating tumors. Specifically, the TLR agonist is a compound of formula (I) and a pharmacologically acceptable salt thereof, and the immune checkpoint inhibitor is selected from a group consisting of a PD-1 inhibitor, a PD-L1 inhibitor, or a CTLA-4 inhibitor. |